AIM ImmunoTech (NYSE:AIM – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.05), MarketWatch Earnings reports. AIM ImmunoTech had a negative net margin of 11,514.29% and a negative return on equity of 53.92%.
AIM ImmunoTech Stock Down 0.0 %
Shares of AIM stock opened at $0.47 on Thursday. AIM ImmunoTech has a 12-month low of $0.29 and a 12-month high of $0.84. The company has a 50 day moving average of $0.50 and a 200-day moving average of $0.54. The firm has a market cap of $22.94 million, a P/E ratio of -1.16 and a beta of -0.06.
Institutional Trading of AIM ImmunoTech
Large investors have recently bought and sold shares of the company. DRW Securities LLC purchased a new stake in AIM ImmunoTech in the 2nd quarter worth about $25,000. Cambridge Investment Research Advisors Inc. bought a new stake in shares of AIM ImmunoTech in the first quarter valued at approximately $49,000. Virtu Financial LLC lifted its stake in shares of AIM ImmunoTech by 34.9% during the 1st quarter. Virtu Financial LLC now owns 50,805 shares of the company’s stock valued at $54,000 after buying an additional 13,148 shares in the last quarter. Renaissance Technologies LLC grew its stake in AIM ImmunoTech by 23.2% in the 1st quarter. Renaissance Technologies LLC now owns 168,708 shares of the company’s stock valued at $73,000 after buying an additional 31,800 shares in the last quarter. Finally, State Street Corp lifted its position in shares of AIM ImmunoTech by 7.9% during the first quarter. State Street Corp now owns 173,103 shares of the company’s stock worth $183,000 after acquiring an additional 12,690 shares in the last quarter. 12.75% of the stock is owned by hedge funds and other institutional investors.
AIM ImmunoTech Company Profile
AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).
- Five stocks we like better than AIM ImmunoTech
- 3 Monster Growth Stocks to Buy Now
- Is it time to buy the dip in Walmart shares?
- How to Most Effectively Use the MarketBeat Earnings Screener
- Unlocking AI investment opportunities in healthcare
- How to Find Cloud Software Company Stocks to Trade and Invest
- New Disney investor propels stock to ranks of best S&P gainers
Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.